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Abstract
Background: Most cases of colorectal cancer are initiated by hyperactivation of the Wnt/β-
catenin pathway due to mutations in the APC tumour suppressor, or in β-catenin itself. A recently
discovered component of this pathway is Legless, which is essential for Wnt-induced transcription
during Drosophila development. Limited functional information is available for its two mammalian
relatives, BCL9 and B9L/BCL9-2: like Legless, these proteins bind to β-catenin, and RNAi-mediated
depletion of B9L/BCL9-2 has revealed that this protein is required for efficient β-catenin-mediated
transcription in mammalian cell lines. No loss-of-function data are available for BCL9.
Methods:  We have used overexpression of dominant-negative forms of BCL9, and RNAi-
mediated depletion, to study its function in human cell lines with elevated Wnt pathway activity,
including colorectal cancer cells.
Results: We found that BCL9 is required for efficient β-catenin-mediated transcription in Wnt-
stimulated HEK 293 cells, and in the SW480 colorectal cancer cell line whose Wnt pathway is
active due to APC  mutation. Dominant-negative mutants of BCL9 indicated that its function
depends not only on its β-catenin ligand, but also on an unknown ligand of its C-terminus. Finally,
we show that BCL9 and B9L are both Wnt-inducible genes, hyperexpressed in colorectal cancer cell
lines, indicating that they are part of a positive feedback loop.
Conclusion: BCL9 is required for efficient β-catenin-mediated transcription in human cell lines
whose Wnt pathway is active, including colorectal cancer cells, indicating its potential as a drug
target in colorectal cancer.
Background
The canonical Wnt signaling pathway changes the tran-
scriptional program of cells, and controls genes with
important functions during normal and malignant devel-
opment [1-3]. A key effector of this pathway is β-catenin,
which is normally phosphorylated and targeted for degra-
dation by the Axin complex that also contains the Adeno-
matous polyposis coli (APC) tumor suppressor. This
complex is inhibited in response to Wnt stimulation,
allowing unphosphorylated β-catenin to accumulate and
bind to the nuclear TCF/LEF factors to stimulate the tran-
scription of Wnt target genes. This trans-activation func-
tion of β-catenin involves the recruitment of a range of
different co-factors that bind to its C-terminus, including
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chromatin modifying and remodelling factors such as
CBP, Brg-1 and SET1 [4-10], TATA-binding protein and
associated factors [11,12], and also a transcriptional elon-
gation factor [13]. Well-established transcriptional target
genes of this pathway include c-myc, AXIN2 and CD44,
whose expression is upregulated in a TCF-dependent fash-
ion in intestinal crypts, and in colorectal neoplasias [14-
19].
Recently, two new nuclear components of the canonical
Wnt pathway have been discovered in Drosophila, called
Pygopus (Pygo) and Legless (Lgs), which are required for
the transcriptional activity of Armadillo (the Drosophila β-
catenin) [20-23]. Each of these components has two
counterparts in mammals (Pygo1 and Pygo2, BCL9 and
BCL9-2/B9L, respectively, whereby BCL9-2 refers to the
murine, and B9L to the human ortholog; below, we shall
either name these proteins individually, or refer to them
collectively as Pygo and BCL9 proteins); siRNA depletion
experiments have indicated a role of Pygo1 and Pygo2,
and of BCL9-2/B9L for efficient TCF-mediated transcrip-
tion in colorectal cancer cells [21,24,25]. Likewise, in ver-
tebrate tissues, Pygo1 and Pygo2 contribute to TCF-
mediated transcription [26-29]. Nothing is known as yet
about the function of BCL9 proteins during vertebrate
development.
Lgs/BCL9 proteins are adaptors between Armadillo/β-cat-
enin and Pygo proteins [20,30], and the interactions of
Lgs with these binding partners are critical for normal
development in flies [31,32]. The molecular roles of Pygo
and Lgs/BCL9 in the Wnt pathway are currently debated:
these proteins could act to recruit an additional transcrip-
tional co-factor that synergizes with the Armadillo/β-cat-
enin co-factors during the transcription of TCF target
genes [13,20,30,33], or they could capture nuclear Arma-
dillo/β-catenin to facilitate its recruitment to TCF target
genes [34,35].
Given their activity in colorectal cancer cells [21,24,25],
Pygo proteins and B9L may provide new targets for Wnt
signaling inhibitors. The latter are particularly promising
since there is evidence that BCL9-2/B9L may predispose
epithelial cells towards a mesenchymal fate [25]. How-
ever, there is very little functional information on BCL9.
We thus set out to study the function of this protein in
human cell lines whose Wnt pathway is active.
Methods
Plasmids
A pCDNA3.1 vector encoding FLAG-tagged human BCL9
was kindly provided by H. Clevers. pCDNA3.1 encoding
FLAG-tagged mouse BCL9-2 [25], B9L or B9LΔCter [24]
have been described; GFP-tagged B9L [24] was also used.
HD2 of human BCL9 (amino acids 343–396) was sub-
cloned into the bacterial expression vector pOPTX (con-
taining an N-terminal thioredoxin tag; kindly provided by
R. Williams). The P348G, L351A, Q355E, HRE358-
360AKQ, L363F, L366K, L373A and E377Q point muta-
tions were introduced into the BCL9 HD2 domain with
the QuickChange mutagenesis kit (Stratagene), and each
construct was confirmed by sequencing. To delete the
Pygo binding site (ΔHD1) in BCL9-2, an internal deletion
of amino acids 238–265 (inclusive) was generated by
PCR-mediated mutagenesis. Similarly, for BCL9ΔC, a stop
codon was inserted into FLAG-BCL9 after amino acid 849.
For the photobleaching experiments, a BCL9 fragment
spanning HD1 and HD2 (HD1+2, amino acids 1–727)
was subcloned into pEGFP-C1 (Clontech) using the
BamHI restriction sites. HA-tagged β-catenin was kindly
provided by A. Ben-Ze'ev [36].
In vitro binding assays
35S-labeled proteins were generated by in vitro transcrip-
tion/translation using T7 polymerase (Promega). For
GST-fusion pull-down assays, glutathione beads contain-
ing 10 μg of GST or GST-ARD (GST fused to amino acids
134–671 of β-catenin [37]) were incubated with in vitro
translated  35S-labeled wild-type (wt) or mutant HD2
domains in PBS containing 0.1% Tween-20 and 1% BSA
(PBS-TB) for 4 hours at 5°C. Beads with bound proteins
were washed five times in PBS-TB, once in PBS and subse-
quently resolved by SDS-PAGE prior to autoradiography.
Cell transfections and transcription assays
HEK 293, HEK 293T and HCT116 cells were grown in
Dulbecco's modified Eagles medium (DMEM) while
SW480 cells were grown in Leibowitz L-15 medium. All
media was supplemented with 10% fetal calf serum. Wnt
pathway activity was induced by treating cells with 20 mM
LiCl (or NaCl, as control) or conditioned media obtained
from L-cells expressing Wnt3A for 6 hours. Cells were
transfected with the Lipofectamine 2000 transfection rea-
gent according to Manufacturer's protocol (Invitrogen).
siRNAs against human BCL9, BCL9-2 and β-catenin were
obtained from Dharmacon; 20 or 80 nmol of 4 pooled
siRNAs were transfected per well (of 24-well or 6-well
plates, respectively). Co-immunoprecipitation or quanti-
tative RT-PCR (RT-qPCR) experiments were carried using
cells grown in 6-well plates and transfected with 1 μg per
well of each plasmid or 80 pmols of siRNAs. For co-
immuno-precipitations, HEK 293 cells were harvested
and lysed 24 hours after transfection; mouse α-FLAG
monoclonal antibody M2 (Sigma Aldrich) was used for
immunoprecipitation. Cells for RT-qPCR were harvested
24- and 48-hours post transfection (with plasmids or siR-
NAs), and RNA was isolated using the TRIZOL reagent
(Invitrogen) according to the manufacturer's protocol.BMC Cancer 2008, 8:199 http://www.biomedcentral.com/1471-2407/8/199
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For immunofluorescence, 250 ng of each plasmid was
used to transfect cells grown on 13 mm coverslips in 24-
well plates. SW480 and HCT116 cells were fixed and
stained with rabbit α-FLAG (Sigma Aldrich) or mouse
monoclonal α-β-catenin C19220 (BD Transduction Labo-
ratories) antibodies 24 hours after transfection as
described [38]. For TOPFLASH reporter assays, 250 ng of
each tester plasmid, or 20 pmols of each siRNA, per well
were used to transfect cells (in 24-well plates), in addition
to 100 ng of TOPFLASH or FOPFLASH plasmids and 100
ng thymidine kinase (TK)-renilla plasmid (as internal
control). TOPFLASH assays were performed using the
Dual-Luciferase Reporter Assay System (Promega) as pre-
viously described [38,39]. Relative luciferase values were
obtained from triplicate samples (from 2–4 independent
experiments) by dividing the firefly luciferase values
(from TOPFLASH or FOPFLASH) by the renilla luciferase
values (from TK-renilla), and standard deviations were
calculated. Paired T-tests were performed to assess statisti-
cal significance where the observed differences were small.
RT-qPCR
cDNA was synthesized from total RNA (2.5 μg) primed
with random hexamers and Superscript III (Invitrogen).
RT-qPCR reactions were carried out with the ABI7900
Taqman thermocycler (Applied Biosystems). Reaction
mixtures for amplification (10 μl) contained 0.5 μl of
each gene expression assay (AB Biotech), 5 μl of 2 × Mas-
ter Mix (AB Biotech) 1 μl of cDNA (~50 ng) and water to
10 μl. The following gene expression assays (from Applied
Biosystems) were used: B9L  (Hs00699441),  HPRT1
(Hs99999909),  AXIN2  (Hs00610344),  CD44
(Hs00153304), and β-Actin  (Hs99999903). Additional
gene target primer and probe sets were designed with the
GenScript qPCR primer design software, and used as fol-
lows (all sequences of primers and probes, respectively,
are 5' to 3'): c-myc, FAM-AAGACAGCGGCAGCCCGAAC-
TAMRA, TCAGAGAAGCTGGCCTCCTA and AGGTA-
CAAGCTGGAGGTGGA; TATA-box binding protein
(TBP), FAM-TACCGCAGCAAACCGCTTGG-TAMRA,
AAAGACCATTGCACTTC GTG and GGTTCGT-
GGCTCTCTTATCC;  BCL9, FAM-CGATTATTCCATCTGA-
GAAGC CCA-TAMRA, CCACCGGAATACCTGAGTTT and
AGGGAAATATTGCAGCGTCT. Primers and probes were
used at a final concentration of 0.2 μM and 0.5 μM respec-
tively. Values for gene expression in each case were calcu-
lated relative to a standard curve of TBP expression whose
consistency from different samples was confirmed in each
case using HPRT1 and β-Actin expression. Comparative
qPCR revealed that the levels of BCL9 and B9L transcripts
in transfected HEK 293 cells were 45× and 90×, respec-
tively, above those of endogenous genes.
Immunoblotting
Cell lysates were prepared in lysis buffer consisting of 50
mM Tris-HCl pH 7.4, 1% NP-40, 150 mM NaCl and 1 mM
MgCl2 and a mixture of protease inhibitors. Total protein
content was determined with Coomassie Plus Protein
Assay Reagent (Pierce). Lysates corresponding to 100 μg
of total protein were analysed by PAGE with 3–8% gradi-
ent Tris-acetate gels (Invitrogen). Proteins were trans-
ferred to a PVDF membrane in transfer buffer (Invitrogen)
at 25 V for 2 hours. The following primary antibodies
were used: mouse α-FLAG monoclonal antibody M2
(Sigma Aldrich), rat α-HA 3F10 (Roche Applied Science),
mouse  α-β-catenin monoclonal antibody C19220 (BD
Transduction Laboratories). For detection of proteins, sec-
ondary antibodies coupled to HRP (Sigma Aldrich) and
ECL Plus Western Blotting Detection Reagents (Amer-
sham Biosciences) were used.
Results
Residues of BCL9 and B9L required for the binding to β-
catenin
The homology domain 2 (HD2) of BCL9 proteins medi-
ates their binding to Armadillo/β-catenin in vitro and in
vivo  [20,24,25,32]. To identify relevant residues within
HD2 of human BCL9, we mutagenized amino acids con-
served between BCL9, BCL9-2/B9L and Lgs (Fig. 1A), and
tested the ability of these mutants to bind the Armadillo
repeat domain (ARD) of β-catenin. Additionally, we gen-
erated two mutants (L363F, L366K) that mimic loss-of-
function alleles of Drosophila lgs (lgs17E, lgs17P; Fig. 1A).
Using pull-down assays, we found that each of these
mutants reduced the binding of HD2 to GST-ARD either
partially, or completely (Fig. 1B). In particular, binding
was eliminated by L366K, consistent with the results for
Lgs [20], but only reduced by L363F (Fig. 1B). Binding
was not affected by mutations in residues flanking HD2
(P348G, E377Q; Fig. 1B). We conclude that the three leu-
cine residues 351, 366, 373 and the HRE cluster 358–360
are critical for the binding between BCL9 and β-catenin,
consistent with the recent structural analysis [40]. For the
following experiments, we decided to use L363F (L>F) as
a partial, and L366K (L>K) as a complete loss-of-function
mutant.
To test the binding of these mutants to β-catenin in vivo,
we introduced them into full-length FLAG-tagged BCL9,
and also generated the corresponding mutants in BCL9-2
(L408F, L411K; Fig. 1A), and co-expressed these with HA-
tagged β-catenin in HEK 293T cells. As expected, HA-β-cat-
enin readily co-immunoprecipitated with wt BCL9, and
also with L363F, but not with L366K (Fig. 1C). Likewise,
HA-β-catenin co-immunoprecipitated with BCL9-2 and
L408F, but not with L411K (Fig. 1D). The converse exper-
iments (immunoprecipitations of HA-β-catenin) showed
the same results (not shown). This is consistent with ourBMC Cancer 2008, 8:199 http://www.biomedcentral.com/1471-2407/8/199
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in vitro binding data (Fig. 1B) and confirms that the L366
and L411 residues in BCL9 and BCL9-2, respectively, are
critical for their binding to β-catenin (though the L>F sub-
stitutions at L363 and L408 are compatible with normal
β-catenin binding, at least at high expression levels).
Importantly, these results indicate that HD2 is the only
domain in BCL9 and BCL9-2 that binds to β-catenin in
vivo.
Different activities of overexpressed BCL9 and BCL9-2 in 
colorectal cancer cell lines
To see whether the L>F and L>K mutations affected the
subcellular distributions of BCL9 or BCL9-2, we expressed
these proteins in SW480 colorectal cancer cells whose Wnt
pathway activity is high, due to mutation of APC [41]. As
expected from previous studies in other mammalian cells
[24,25], BCL9 was distributed throughout the cytoplasm
and nucleus (Fig. 2A) while BCL9-2 was strictly nuclear
(Fig. 2B; the subcellular distribution of B9L was indistin-
guishable from that of BCL9-2; not shown). Both proteins
showed a tendency to form puncta, however, in neither
case could we detect significant differences in the subcel-
lular distributions between wt and mutants (not shown).
We also used photobleaching experiments (essentially as
described [34,42]) to confirm that GFP-tagged
BCL9(HD1+2) is a highly dynamic nuclear-cytoplasmic
Mutants of BCL9 proteins that cannot bind to β-catenin Figure 1
Mutants of BCL9 proteins that cannot bind to β-catenin. A, Sequence alignments of the HD2 domains of Lgs, BCL9 and 
BCL9-2/B9L (residue numbers in the latter two refer to mouse or human HD2 sequences, which are identical). Individual con-
served residues (boxed) were mutated, and semiquantitative estimates of their in vitro binding affinities (++/+/-) to the β-catenin 
ARD are given underneath. B, pull-down assays between in vitro translated wt and mutant BCL9 HD2 and GST-ARD, as indi-
cated; input lanes, 5% of the total binding reaction. C and D, co-immunoprecipitations of FLAG-tagged wt and mutant BCL9 or 
BCL9-2 with HA-β-catenin expressed in HEK 293T cells; bottom panels, protein expression levels in the lysates.
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Subcellular distribution and transactivation potential of wt and mutant BCL9 and B9L Figure 2
Subcellular distribution and transactivation potential of wt and mutant BCL9 and B9L. A and B, SW480 cells over-
expressing FLAG-BCL9 or FLAG-BCL9-2, fixed and stained with antibodies against β-catenin and FLAG, as indicated in panels 
(the staining pattern of GFP-B9L was similar to that of FLAG-BCL9-2; not shown). C-E, TOPFLASH assays in SW480 and Wnt-
stimulated HEK 293 cells (as indicated in panels), expressing wt or mutant FLAG-BCL9 or FLAG-BCL9-2 (see text). Control 
FOPFLASH assays were also conducted, but the values were less than 5% of TOPFLASH values and did not vary significantly 
between samples (not shown). Standard deviations are given by bars, and statistical significance relative to values from cells 
transfected with pCDNA3 (arbitrarily set to 100) is indicated above bars (*, p < 0.05; **, p < 0.001).
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shuttling protein, like Lgs [34,42], but we were unable to
detect any significant differences in the shuttling rates
between wt and mutant proteins (not shown).
Given the adaptor role of Lgs/BCL9 [20], full activity
would require both an intact HD2 and Pygo-binding
domain (called homology domain 1, or HD1). To test
this, we overexpressed the L366K and L411K mutants, and
BCL9 and BCL9-2 mutants with small internal HD1 dele-
tions (ΔHD1), as well as ΔHD1 L366K and ΔHD1 L411K
double-mutants in colorectal cancer cells, and we exam-
ined their effects on the Wnt pathway activity of these cells
by using TCF reporter activity (TOPFLASH) as a specific
and quantitative read-out [39]. We expected one of three
outcomes for these ligand-binding mutants: namely, a
mutant could be (1) less active than its wt counterpart,
implying that the corresponding ligand is required for the
function of the wt protein; (2) dominant-negative (DN),
suggesting that the mutant protein sequesters a ligand
required for the function of the wt protein; or (3) as active
as the wt, indicating that the corresponding ligand is not
required for the function of the wt protein, at least after
overexpression. In particular, we were interested in the
behaviour of the double-mutants which cannot bind to
either of their known ligands, β-catenin or Pygo: if these
were DN, then this would suggest an additional func-
tional ligand of BCL9 proteins.
In SW480 cells, we found that overexpression of wt BCL9
did not affect TOPFLASH activity (Fig. 2C), consistent
with previous results of BCL9 overexpression in Wnt-stim-
ulated HEK 293 cells [24]. Likewise, we could not detect
any DN effects with any of the BCL9 mutants (Fig. 2C),
which were expressed at similarly high levels as the wt
(not shown), but this is most likely due to the relatively
low transfection efficiency of these cells (see also below,
for the behaviour of these mutants in HEK 293 cells
whose transfection efficiency is higher). In contrast, over-
expressed wt BCL9-2 potentiated TCF reporter activity
approximately two-fold in SW480 cells (Fig. 2D), consist-
ent with previous results with B9L [24]. However, none of
the BCL9-2 mutants displayed any significant stimulatory
activity (Fig. 2D). This indicates that the function of BCL9-
2 in TCF-mediated transcription of these cells depends on
its ability to bind to β-catenin and Pygo proteins.
We also tested wt and mutant BCL9 proteins in HEK 293
cells transiently stimulated with Wnt3A, since this pro-
vides a more sensitive assay (partly due to the higher
transfection efficiency of these cells). We optimized this
assay, minimizing the Wnt exposure time as much as pos-
sible, which allowed us to focus on the primary transcrip-
tional Wnt response and to avoid secondary knock-on
effects. We thus found that culturing 293 cells in the pres-
ence of Wnt3A for 6 hours resulted in a 2× increase in
TOPFLASH activity (Fig. 2E). Like in SW480 cells, overex-
pression of wt BCL9 did not further increase this activity
(Fig. 2E). However, overexpression of L366K, but not of
ΔHD1, showed consistently a slight DN effect in reducing
TOPFLASH activity compared to the control (Fig. 2E).
This DN effect did not appear to be due to the sequestra-
tion of Pygo, since it was still detectable with the overex-
pressed double-mutant L366K ΔHD1 (Fig. 2E). This
suggests that this double-mutant BCL9 may sequester a
functionally important ligand other than β-catenin and
Pygo (see below).
As in SW480 cells, overexpression of BCL9-2 in Wnt3A-
stimulated HEK 293 cells resulted in a 2× increase of TOP-
FLASH activity (Fig. 2E). Its ΔHD1 mutant version also
stimulated the TOPFLASH reporter to some extent (by
~50%), whereas L411K showed a slight DN effect, like its
L366K counterpart (Fig. 2E), although the ΔHD1 L411K
double-mutant appeared neutral and inactive (Fig. 2E). It
thus seemed that the latter, unlike its BCL9 counterpart,
failed to behave as a DN, but this may have been due to
technical reasons (e.g. the expression levels of ΔHD1
L411K were significantly lower than those of L366K
ΔHD1; not shown; see also Fig. 1C, D). Taken together,
these results indicated that both BCL9 and BCL9-2 rely on
their binding to β-catenin and Pygo, and possibly on an
additional unknown ligand (at least in the case of BCL9),
for their function in mediating Wnt-dependent transcrip-
tion.
BCL9 and B9L are Wnt target genes
We also tested the effects of overexpressed wt and mutant
BCL9 proteins on the Wnt inducibility of endogenous
TCF-mediated transcription. Two of the best-established
TCF target genes in intestinal epithelial and colorectal can-
cer cells are c-myc and AXIN2 [14,16-19]. We stimulated
HEK 293 cells for 6 hours with either Wnt3A-conditioned
medium, or with LiCl (an inhibitor of GSK3β), and we
monitored the transcript levels of these genes by RT-
qPCR. As internal controls, we measured the expression
levels of TATA-box binding protein (TBP), β-actin and the
house-keeping gene HPRT. As expected, we observed a 2–
2.5× upregulation of c-myc  and  AXIN2  transcripts in
response to both Wnt3A and LiCl stimulation (Fig. 3A–
C), while the transcript levels of the three internal control
genes did not change after these treatments. Interestingly,
we also discovered that the transcript levels of both BCL9
and B9L were upregulated to a similar degree (~2× and
~2.5×, respectively) after Wnt stimulation (Fig. 3A).
Therefore, BCL9 and B9L are themselves Wnt-responsive,
and are thus likely to represent TCF target genes.
Next, we tested the effects of overexpressed wt and mutant
BCL9 proteins on the Wnt-induced expression levels of c-
myc and AXIN2. As expected from the TOPFLASH assaysBMC Cancer 2008, 8:199 http://www.biomedcentral.com/1471-2407/8/199
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(Fig. 2E), overexpressed wt BCL9 did not stimulate the
Wnt-induced expression of these genes further (Fig. 3B),
however overexpressed BCL9-2 synergized with Wnt3A to
increase the transcript levels of AXIN2 and c-myc by ~30%
(Fig. 3C). Likewise, the BCL9 mutants behaved the same
as in the TOPFLASH assays (Fig. 2E), with L366K and
L366K ΔHD1 displaying clear DN effects (Fig. 3B). In the
case of BCL9-2, each mutant was inactive (i.e. no synergy
with Wnt stimulation was observed), and we detected
slight albeit statistically significant DN effects of ΔHD1
and L411K ΔHD1 for one target gene each (Fig. 3C). Once
again, the DN effect of the double-mutant suggested that
BCL9-2, like BCL9, may have an additional functionally
important ligand. Taken together, these results fully con-
firmed those from the TOPFLASH assays, and suggested
that the functions of BCL9 proteins regarding the tran-
scriptional Wnt response of endogenous target genes are
mediated by Pygo and β-catenin, and possibly also
involve a third ligand (see below).
Given the Wnt-responsiveness of BCL9 and B9L in HEK
293 cells, we wondered whether these genes might be
hyperexpressed in colorectal cancer cell lines. We thus
used RT-qPCR to monitor their transcript levels in SW480
cells, and also in HCT116 cells whose elevated Wnt path-
way activity is due to an activating mutation in β-catenin
[41]. We found that the BCL9 transcript levels were com-
parable in both cell lines to those in Wnt-stimulated HEK
293 cells, whereas the B9L transcript levels were consider-
ably higher in the colorectal cell lines (35× and 50× higher
in SW480 and HCT116 cells, respectively, compared to
unstimulated HEK 293 cells; Fig. 3D). These elevated B9L
transcript levels are similar to those of BCL9 in the same
cell lines (Fig. 3D). As a comparison, we also measured
BCL9 and B9L are Wnt-inducible genes Figure 3
BCL9 and B9L are Wnt-inducible genes. A, Transcript levels of BCL9 and B9L in comparison to AXIN2, as measured by 
RT-qPCR, after induction of Wnt pathway activity in HEK 293 cells by addition of Wnt3A-conditioned medium, or 20 mM LiCl, 
for 6 hours. Statistical significance (p < 0.01) relative to Wnt-stimulated cells (arbitrarily set to 100) is indicated by asterisks. B 
and C, Transcript levels of c-myc and AXIN2 in Wnt-stimulated HEK 293 cells, measured by RT-qPCR as in A, after overexpres-
sion of wt or mutant FLAG-BCL9, or FLAG-BCL9-2. Statistical significance relative to Wnt-stimulated cells (arbitrarily set to 
100) is indicated by asterisks (*, p < 0.05; **, p < 0.005). D, Transcript levels of BCL9, B9L, AXIN2, c-myc and CD44 relative to 
TBP (as internal control) in HEK 293 (with or without Wnt stimulation), SW480 or HCT116 cells. Statistical significance rela-
tive to uninduced HEK 293 cells is indicated by asterisks (*, p < 0.01; **, p < 0.001).
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the expression levels of AXIN2 and c-myc, and of CD44
whose expression in the intestinal epithelium is control-
led by TCF and APC [15]. As expected, all three genes are
highly expressed in SW480 cells (25×, 6× and ~100×
higher, respectively, than in unstimulated HEK 293 cells;
Fig. 3D), although in HCT116 cells, only CD44 is overex-
pressed, while the transcript levels of AXIN2 and c-MYC
are lower than in Wnt-stimulated 293 cells (Fig. 3D), in
the case of AXIN2 due to epigenetic silencing by DNA
methylation which has been observed in colorectal cancer
cell lines with microsatellite instability, such as HCT116
[43]. Thus, B9L and to some extent BCL9 are hyperex-
pressed in colorectal cancer cells compared to unstimu-
lated HEK 293 cells – in the case of B9L, more than an
order of magnitude, much like some of the other TCF tar-
get genes.
Both BCL9 and B9L are required for Wnt pathway activity
BCL9-2/B9L has previously been shown to be a positive
regulator of Wnt signaling in Wnt-stimulated mammalian
cells, and in SW480 colorectal cancer cells [24,25]. This is
consistent with the DN behaviour of its mutant version,
L411K, which cannot bind to β-catenin (Fig. 1D). Given
that the corresponding mutant of BCL9 (L366K) showed
similar DN effects (at least in Wnt-stimulated HEK 293
cells), we asked whether BCL9 is also required for efficient
Wnt pathway activity in SW480 cells.
We thus used siRNA-mediated depletion to test this, and
also to assess the relative contributions of BCL9 and B9L
to TCF-mediated transcription in SW480 cells. This
allowed us to reduce the transcript levels of BCL9 to
~50%, and those of B9L to ~30% of their normal levels in
these cells (Fig. 4A); under the same conditions, we were
able to deplete the levels of β-catenin transcripts to ~25%
(not shown). We found that the expression levels of c-myc
and AXIN2 were reduced after depletion of BCL9 to a sim-
ilar degree as after depletion of B9L, or after depletion of
β-catenin transcripts (Fig. 4A). B9L expression was also
reduced after BCL9 depletion (which thus mimics a dou-
ble knock-down of both paralogs, albeit a partial one)
although the converse was not true, possibly because this
gene is only mildly Wnt-inducible, and is less hyperactive
than B9L in colorectal cancer cell lines (see Fig. 3). These
results indicate that BCL9 is required for efficient TCF-
mediated transcription in these colorectal cancer cells,
similarly to B9L and β-catenin.
We also depleted BCL9 transcripts in Wnt-stimulated HEK
293 cells, to test the role of BCL9 in TCF-mediated tran-
scription under transient Wnt signaling conditions. Again,
we found marked reductions of c-myc, AXIN2 and B9L
after BCL9 depletion, similarly as after depletion of B9L
(Fig. 4B). Indeed, the effects on Wnt target gene expres-
sion appeared stronger in these cells, most likely due to
their higher transfection efficiency (i.e. a higher fraction of
cells experienced RNAi-mediated depletion). We con-
clude that BCL9, like B9L, is a positive regulator of Wnt-
induced transcription in HEK 293 cells.
The C-termini of BCL9 proteins are required for their 
function in Wnt signaling
Previous work revealed a DN effect of a C-terminal dele-
tion of B9L in colorectal cancer cells, suggesting a role of
the C-terminus of B9L in its Wnt response [24]. Likewise,
our result that the BCL9 double-mutant behaved as a DN,
despite being defective in Pygo and β-catenin binding (see
above), suggested that this protein may bind to an addi-
BCL9 is required for the transcription of endogenous Wnt target genes Figure 4
BCL9 is required for the transcription of endogenous Wnt target genes. Transcript levels of BCL9, B9L, c-MYC and 
AXIN2, as measured by RT-qPCR, in (A) SW480 cells or (B) Wnt-induced HEK 293 cells (as in Fig. 3), treated with siRNA to 
deplete β-catenin, BCL9 or B9L. Statistical significance (*, p < 0.01 and **, p < 0.001) relative to controls (set arbitrarily to 
100%) is indicated above bars.
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tional ligand required for its function in Wnt signaling.
We thus generated a C-terminal deletion (ΔC) of BCL9, to
test whether this would behave as a DN in Wnt-stimulated
HEK 293 cells. Furthermore, we introduced the L366K
and ΔHD1 single and double mutations into this C-termi-
nal truncation, and also into the ΔC truncation of B9L
[24], to ask whether the DN effect(s) would be abolished
if β-catenin and/or Pygo binding was eliminated.
Indeed, the ΔC mutant of BCL9 showed a mild DN effect
on the TOPFLASH activity of Wnt-stimulated HEK 293
cells (Fig. 5A). By comparison, B9L ΔC behaved as a more
potent DN [24], reducing the TOPFLASH values almost to
those measured in unstimulated cells (Fig. 5B), possibly
because it could compete more effectively with endog-
enous B9L (whose expression level is far lower than that
of BCL9; Fig. 3D) and is targeted to the nucleus more effi-
ciently than BCL9 (Fig. 2A, B). Interestingly though, in
both cases, the DN effects remained detectable in the ΔC
ΔHD1 double-mutants, but was eliminated in the ΔC
L366K/L411K double-mutants, and in the triple-mutants
(Fig. 5A,B), all of which are defective in β-catenin binding.
These results indicated that the C-terminus of BCL9, like
that of B9L, harbours a function in TCF-mediated tran-
scription, thus explaining why the ΔHD1 L366K and
ΔHD1 L411K double-mutants behave as DNs (Fig. 2E; 3B,
C). Furthermore, the results from all three types of dou-
ble-mutants imply that the putative sequestration of β-cat-
enin (by ΔC  ΔHD1) or C-terminal ligand (by ΔHD1
L366K and ΔHD1 L411K) reduced Wnt-mediated tran-
scription, whereas sequestration of Pygo (by ΔC L366K
and ΔC L411K) did not affect this process.
Discussion
The function of BCL9 and B9L depends on their binding to 
β-catenin
Our mutational analysis of HD2 revealed multiple resi-
dues in this domain that are critical for β-catenin binding
in vitro, including three leucine residues whose mutation
ablated binding. This is fully consistent with recent struc-
tural data: HD2 forms an α-helix which contacts the N-ter-
minal end of the ARD of β-catenin, whereby two of these
leucines (L366, L373) are located at the interface between
the two domains and are engaged in direct contacts with
β-catenin (the third, L351, was not visible in the structure)
[40]. Importantly, the individual L>K mutations which
abolished β-catenin binding in vitro also eliminated asso-
ciation of BCL9 and B9L with β-catenin in vivo, so HD2 is
the only domain through which these proteins can bind
to β-catenin in cells. Consistent with this, the correspond-
ing L>K mutation in Drosophila (in the lgs17P allele) results
in Lgs loss-of-function, and loss of Armadillo binding
Requirement of the C-terminus of BCL9 for Wnt-induced transcription Figure 5
Requirement of the C-terminus of BCL9 for Wnt-induced transcription. Transcript levels of c-MYC and AXIN2, as 
measured by RT-qPCR, in Wnt-induced HEK 293 cells (as in Fig. 3) after overexpression of wt or mutant (A) FLAG-BCL9 or 
(B) FLAG-BCL9-2. Statistical significance (p < 0.01) relative to Wnt-stimulated control cells (set arbitrarily to 100%) is indicated 
by asterisks above bars.
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[20]. Somewhat puzzlingly, the L>F mutants reduced β-
catenin binding of BCL9 proteins only mildly in vitro, and
not detectably in vivo (Fig. 1), so it is less clear why the cor-
responding mutation in the lgs17E allele should inactivate
Lgs in Drosophila development [20].
BCL9 proteins are necessary for efficient TCF-dependent 
transcription
The functional link between BCL9 and β-catenin indi-
cated a role for BCL9 in Wnt signaling. Indeed, our loss-
of-function analysis by RNAi in Wnt-stimulated HEK 293
and SW480 cells provided strong evidence for this, reveal-
ing that BCL9 is required for efficient TCF-mediated
reporter gene transcription and for Wnt-inducibility of
endogenous TCF target genes. Therefore, BCL9 is a posi-
tive regulator of the Wnt pathway in human cells, simi-
larly to its relative B9L [24,25], and to its Lgs counterpart
in Drosophila [20].
We confirmed earlier findings that BCL9 exhibits a subcel-
lular distribution distinct from that of B9L/BCL9-2
[24,25]: BCL9 was found throughout the cytoplasm and
nucleus after overexpression, whereas B9L was entirely
nuclear (Fig. 2A, B). This constitutive nuclear location of
B9L is due to a nuclear localization sequence (NLS) in its
N-terminus [25]. In contrast, BCL9 is a 'conditionally
nuclear' protein that can shuttle in and out of the nucleus,
like Lgs [34,42]. Indeed, the nuclear location of Lgs
depends entirely on its binding to Pygo [34], and the same
may also be the case for BCL9. In turn, Pygo proteins are
constitutively nuclear by virtue of their own NLS (e.g.
[20,21,31,34,44]), and Pygo-BCL9/Lgs complexes can
bind to methylated histone H3 tail through the PHD fin-
gers of Pygo [45]. Notably, in Drosophila, Pygo is associ-
ated with dTCF target genes even in the absence of
Wingless signaling [35]. Pygo proteins thus appear to be
nuclear retention factors for the conditionally nuclear
BCL9 proteins, and may recruit them to TCF target genes.
It is unclear why vertebrates have also evolved a constitu-
tively nuclear version of BCL9/Lgs. Given the Wnt-induc-
ibility of B9L in human cells and its overexpression in
colorectal cancer cells, it is conceivable that the constitu-
tively nuclear B9L/BCL9-2 proteins serve to maintain, or
boost, Wnt-mediated transcription in cells whose Wnt
pathway is persistently active (see below).
The distinct subcellular locations of BCL9 and B9L may
explain why only B9L, but not BCL9, is able to potentiate
Wnt-induced transcription when overexpressed in HEK
293 and SW480 cells (Fig. 2D, 3B, C; Fig. 5). It is likely
that the nuclear retention factors of BCL9 – e.g. the Pygo
proteins – are limiting under these conditions, especially
since endogenous BCL9 is also expressed at comparatively
high levels in both cell types (Fig. 3D). Note that,
although the constitutive nuclear location of B9L is likely
to be independent of Pygo, its function nevertheless relied
on its interaction with Pygo, given that the ΔHD1 mutant
of B9L was unable to stimulate Wnt-mediated transcrip-
tion (Fig. 2D, 3C).
Apart from their distinct subcellular distributions and
overexpression phenotypes, BCL9 and B9L appear to be
equivalent regarding their roles in Wnt signaling. In par-
ticular, their in vivo associations with β-catenin were com-
parable (Fig. 1), probably reflecting similar binding
affinities, given that their β-catenin-binding residues in
HD2 are highly conserved [40]. Likewise, the Pygo-bind-
ing residues in HD1 are conserved between the two BCL9
proteins [45], implying comparable affinities to Pygo as
well. Of course, there may be other differences between
BCL9 and B9L with regard to unknown ligands and/or
functions (see below).
Evidence for a functional ligand of the C-termini of BCL9 
proteins
Two pieces of evidence indicated an additional unknown
ligand of the BCL9 C-terminus that is critical for the func-
tion of BCL9 in Wnt-mediated transcription. Firstly, a
BCL9 double-mutant whose binding to β-catenin and
Pygo was eliminated behaved as a DN in Wnt signaling
assays. This DN effect is unlikely due to direct interference
with endogenous BCL9 (and/or B9L) via dimerization,
since we were neither able to detect self-association of dif-
ferently tagged BCL9 proteins, nor heterodimerization
between BCL9 and B9L, in transfected HEK 293 cells; lack
of interaction between the two proteins was also apparent
in sensitive in vivo recruitment assays (i.e. B9L was unable
to recruit BCL9 into the nucleus on co-expression; J. W.,
unpublished data). Secondly, a C-terminal truncation of
BCL9 also behaved as a DN in Wnt-stimulated mamma-
lian cells, like the equivalent truncation of B9L [24]. This
was somewhat surprising, given that an equivalent trunca-
tion of Lgs was able to rescue lgs mutants in Drosophila
[20]. However, it is worth noting that these rescue assays
involved overexpression, and therefore possibly masked a
function of the Lgs C-terminus. Indeed, 1 of the 6 known
lgs mutations results in a similar C-terminal truncation
[20], indicating that the C-terminus of Lgs does in fact
have an important function during normal development
in Drosophila.
Evidence for an additional ligand of BCL9 proteins with a
function in Wnt signaling was also provided by the dou-
ble-mutants whose binding to Pygo and β-catenin was
eliminated: these behaved as DNs, possibly by sequester-
ing a functionally important ligand. If so, and if this third
ligand bound to the C-terminus of BCL9 proteins, then
the DN effects of the double-mutants should be elimi-
nated in triple-mutants that also lack the C-terminus,
which was indeed the case. It thus appears that the triple-BMC Cancer 2008, 8:199 http://www.biomedcentral.com/1471-2407/8/199
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mutants are no longer able to sequester any functional lig-
and, supporting the notion that BCL9 proteins have three
rather than two functionally important ligands. Our evi-
dence for a third C-terminal ligand of BCL9 proteins
argues against the simple adaptor hypothesis as initially
proposed, which envisaged that the sole function of BCL9
proteins was to link Pygo and Armadillo/β-catenin [20].
During the final stages of manuscript preparations, a
study was published that uncovered a cell-type specific
function of BCL9 in TCF-responsive transcription in B cell
lines [46]. This function appears to be independent of
Pygo proteins, but reliant on a trans-activation domain in
the C-terminus of BCL9. It is conceivable that this domain
is responsible for the dominant-negative effects of our C-
terminal BCL9 (and B9L) deletions.
BCL9 and B9L are Wnt target genes
In the course of our analysis, we discovered that BCL9 and
B9L  are both Wnt-inducible genes, and that they are
hyperexpressed in colorectal cancer cells whose Wnt path-
way is constitutively active. Therefore, both genes are
likely to be TCF target genes, much like c-myc and AXIN2
[14,16,17]. In particular, B9L  expression was highly
responsive to changes in Wnt pathway activity, and its
hyperexpression in colorectal cancer cells was pro-
nounced. Notably, high levels of B9L transcripts have also
been found in 6 of 14 of colorectal tumour samples with
elevated Wnt pathway activity [24], and the level of B9L
overexpression correlated with the progression from
benign colorectal adenomas to invasive carcinomas [47].
Our findings suggest that BCL9 and B9L are part of a pos-
itive feedback mechanism. In particular, B9L may func-
tion to maintain, or boost, TCF-mediated transcription
once initiated by the stimulation of cells by extracellular
Wnt ligand. Indeed, overexpression of B9L and BCL9 may
contribute to, or even confer, persistent pathway activity
that is independent of Wnt ligand, for example in colorec-
tal tumours whose progression may thus be promoted by
these proteins.
The potential of BCL9 as a drug target in colorectal cancer
Although the Wnt/β-catenin pathway is an important can-
cer pathway, there are no well-established, validated small
molecule inhibitors of this pathway to date. The likely rea-
son for this is that the cancer-promoting Wnt pathway
mutations typically occur at the level of, or immediately
above, β-catenin [2,48]. However, there are no known
enzymes below activated β-catenin that could be inhib-
ited, and the protein interaction surface between β-cat-
enin and TCF is highly unsuitable for disruption by small
molecule inhibitors since it is extensive, and because neg-
ative regulators of β-catenin such as Axin and APC bind to
the same TCF-interacting surface of β-catenin [49].
Our evidence for the requirement of BCL9 in the TCF-
dependent transcription of colorectal cancer cells, and its
hyperexpression in these cells, has revealed its potential as
a target for inhibitory drugs. Furthermore, the potential
for disruption of the binding between β-catenin and BCL9
is indicated by our result that single point mutations in
HD2 disrupt the association of β-catenin and BCL9, or
B9L, in vitro and in vivo (Fig. 1), consistent with the struc-
tural analysis of the β-catenin-BCL9 complex, which also
illustrates the importance of individual residues for their
mutual interaction [40]. However, further validation of
BCL9 proteins as drug targets in colorectal cancer will be
required, including the analysis of their function in Wnt
signaling during mammalian development and in adult
tissue homeostasis, and of their role in promoting intesti-
nal tumorigenesis in animal models.
Conclusion
Our loss-of-function analysis of BCL9 in human cell lines
has led to the following three conclusions. Firstly, BCL9 is
required for efficient TCF-mediated transcription in Wnt-
stimulated and colorectal cancer cells. Secondly, this func-
tion of BCL9 depends on β-catenin, but also on its C-ter-
minus, implying that this conserved part of the protein
binds to an unknown ligand that is important for its Wnt-
related function. Thirdly, both BCL9 and B9L are Wnt-
inducible genes that are hyperexpressed in colorectal can-
cer cell lines, indicating that they are part of a positive
feedback loop, reinforcing Wnt pathway activity. The
functional importance and hyperexpression of BCL9 in
colorectal cancer cells indicates the potential of this pro-
tein as a cancer drug target.
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